IL-10 induces the development of immunosuppressive CD14+ HLA-DRlow/- monocytes in B-cell non-Hodgkin lymphoma

Blood Cancer Journal

Volumn 5, Issue 7, 2015, Pages

  Xiu, B ^a,b   Lin, Y ^b   Grote, D M ^b   Ziesmer, S C ^b   Gustafson, M P ^b   Maas, M L ^b   Zhang, Z ^b   Dietz, A B ^b   Porrata, L F ^b   Novak, A J ^b   Liang, A B ^a   Yang, Z Z ^b   Ansell, S M ^b  

^a TONGJI UNIVERSITY   (China)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; IL10 PROTEIN, HUMAN;

ARTICLE; CELL COUNT; CELL EXPANSION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOCYTE PROLIFERATION; LYMPHOMA CELL; MONOCYTE; NONHODGKIN LYMPHOMA; T LYMPHOCYTE ACTIVATION; B LYMPHOCYTE; BLOOD; CASE CONTROL STUDY; CELL CULTURE; CELL PROLIFERATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE;

ANTIGENS, CD14; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; HLA-DR ANTIGENS; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; LYMPHOMA, NON-HODGKIN; MONOCYTES; T-LYMPHOCYTES;

EID: 84989336939     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.56     Document Type: Article

References (37)

1. Rosenquist R, Davi F, Ghia P. The microenvironment in lymphomas-dissecting the complex crosstalk between tumor cells and 'by-stander' cells. Semin Cancer Biol 2014; 24: 1-2.
2. Yang ZZ, Ansell SM. The tumor microenvironment in follicular lymphoma. Clin Adv Hematol Oncol 2012; 10: 810-818.
3. Juszczynski P, Nowak J, Warzocha K. Host immune response in B-cell lymphomas: Friend or foe? Arch Immunol Ther Exp (Warsz) 2008; 56: 245-255.
4. Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 2014; 14: 517-534.
5. Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007; 13(2 Pt 1): 388-397.
6. Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001; 19: 720-726.
7. Siddiqui M, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 2006; 134: 596-601.
8. Porrata LF, Ristow K, Witzig TE, Tuinistra N, Habermann TM, Inwards DJ et al. Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas. Leukemia 2007; 21: 2554-2556.
9. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169-2174.
10. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008; 26: 440-446.
11. Clear AJ, Lee AM, Calaminici M, Ramsay AG, Morris KJ, Hallam S et al. Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. Blood 2010; 115: 5053-5056.
12. Marchesi F, Cirillo M, Bianchi A, Gately M, Olimpieri OM, Cerchiara E et al. High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. Hematol Oncol 2014; 33: 110-112.
13. Yamamoto W, Nakamura N, Tomita N, Takeuchi K, Ishii Y, Takahashi H et al. Human leukocyte antigen-DR expression on flow cytometry and tumorassociated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: Retrospective cohort study. Leuk Lymphoma 2014; 55: 2721-2727.
14. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DR(low)/ - monocytes in B-cell non-Hodgkin lymphoma. Blood 2011; 117: 872-881.
15. Khalifa KA BH, Radwan WM, Shehata MA, Bassuoni MA. CD14+HLA-DRlow/ - monocytes as indicator of disease aggressiveness in B-cell non-Hodgkin lymphoma. Int J Lab Hematol 2014; 36: 650-655.
16. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy-review of a new approach. Pharmacol Rev 2003; 55: 241-269.
17. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-1220.
18. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444-3451.
19. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: A counterpoint. J Leukoc Biol 2005; 78: 1043-1051.
20. Sharma S, Stolina M, Lin Y, Gardner B, Miller PW, Kronenberg M et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999; 163: 5020-5028.
21. Charbonneau B, Maurer MJ, Ansell SM, Slager SL, Fredericksen ZS, Ziesmer SC et al. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control study. Cytokine 2012; 60: 882-889.
22. Gupta M, Han JJ, Stenson M, Maurer M, Wellik L, Hu G et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: A mechanism of aberrant JAK2 activation. Blood 2012; 119: 2844-2853.
23. Conroy SM, Maskarinec G, Morimoto Y, Franke AA, Cooney RV, Wilkens LR et al. Non-hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: The multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2013; 22: 337-347.
24. Gustafson MP, Lin Y, Maas ML, Van Keulen VP, Johnston PB, Peikert T et al. A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans. PLoS One 2015; 10: E0121546.
25. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: E74-e80.
26. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159-2169.
27. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25: 2546-2553.
28. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135: 234-243.
29. Chikamatsu K, Sakakura K, Toyoda M, Takahashi K, Yamamoto T, Masuyama K. Immunosuppressive activity of CD14+ HLA-DR cells in squamous cell carcinoma of the head and neck. Cancer Sci 2012; 103: 976-983.
30. Gustafson MP, Lin Y, New KC, Bulur PA, O'Neill BP, Gastineau DA et al. Systemic immune suppression in glioblastoma: The interplay between CD14+HLADRlo/ neg monocytes, tumor factors, and dexamethasone. Neuro Oncol 2010; 12: 631-644.
31. Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X et al. Immunosuppressive CD14+HLA-DRlow/ - monocytes in prostate cancer. Prostate 2010; 70: 443-455.
32. Gustafson MP, Abraham RS, Lin Y, Wu W, Gastineau DA, Zent CS et al. Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). Br J Haematol 2012; 156: 674-676.
33. Jitschin R, Braun M, Buttner M, Dettmer-Wilde K, Bricks J, Berger J et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 2014; 124: 750-760.
34. Arihara F, Mizukoshi E, Kitahara M, Takata Y, Arai K, Yamashita T et al. Increase in CD14+HLA-DR - /low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother 2013; 62: 1421-1430.
35. Huang A, Zhang B, Wang B, Zhang F, Fan KX, Guo YJ. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother 2013; 62: 1439-1451.
36. Vari F, Gandhi MK. Broad-spectrum immunosuppression by classless monocytes in non-Hodgkin's lymphoma. Immunotherapy 2011; 3: 723-726.
37. Gustafson MP, Lin Y, LaPlant B, Liwski CJ, Maas ML, League SC et al. Immune monitoring using the predictive power of immune profiles. J Immunother Cancer 2013; 1: 7.